Latest news with #respiratoryfailure
Yahoo
05-08-2025
- Business
- Yahoo
With 6.4% CAGR, Extracorporeal CO2 Removal Devices Market to Reach US$184.36 million by 2031
NEW YORK, Aug 5, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global extracorporeal CO2 removal devices market is witnessing substantial growth with the increasing cases of chronic obstructive pulmonary diseases (COPD) and the growing geriatric population. The extracorporeal CO2 removal devices market is expected to reach US$184.36 million by 2031 from US$112.50 million in 2024; it is anticipated to record a CAGR of 6.4% during the forecast period. Extracorporeal CO₂ removal devices are innovative technologies that directly remove CO₂ from the blood; these devices operate much like dialysis. Extracorporeal CO₂ removal systems are primarily utilized in critical care involving patients with acute respiratory failure and COPD. Extracorporeal CO₂ removal devices allow clinicians to undertake lower-set ventilator parameters and diminish ventilator-induced lung injuries. The study focuses on an array of products and technologies that are expected to fuel the demand in the coming years. The report carries an in-depth analysis of Extracorporeal CO2 Removal Devices Market trends, key players, and future opportunities. Check valuable insights in Extracorporeal CO2 Removal Devices Market report. You can easily get a sample PDF of the report - Overview of Report Findings Market Growth: The global market is expected to continue to experience steady growth as the incidence of respiratory diseases continues to rise. Advancements in technologies create lucrative avenues for extracorporeal CO₂ removal systems, and hospitals and intensive care units (ICUs) adopt these devices prominently in clinical practice. Furthermore, increasing general awareness about the benefits of early CO₂ removal and the aging demographics have promoted demand for extracorporeal CO₂ removal devices. Subsequently, ongoing clinical trials and new product development by major market players are continuing to promote the expansion of the market. Rising Prevalence of Respiratory Diseases: The increasing incidence of respiratory diseases such as COPD, acute respiratory distress syndrome (ARDS), and severe asthma is also driving growth in the global extracorporeal CO₂ removal devices market. Impairment of lung function from these diseases is frequently characterized by hypercapnia, an abnormal elevation of CO₂ in the bloodstream, which is extracorporeal carbon dioxide removal devices offer a simple and minimally invasive method of CO₂ removal from the bloodstream that can actually stabilize patients and allow them to reduce their use of invasive mechanical worldwide burden of respiratory disorders is progressing rapidly (and will progress further, primarily from air quality degradation and age distribution of populations, as well as the use of tobacco); the demand is clearly high for advanced forms of supportive technologies such as extracorporeal CO₂ removal systems. In addition, the COVID-19 pandemic revealed unprecedented requirements for alternative methods of respiratory support; it demonstrated a large clinical interest and adoption of extracorporeal CO₂ removal systems, which heightened interest with regard to clinical innovation, investment, and clinical uses, and overall larger market for these life-saving devices. Technological Innovation: Technological innovations within the extracorporeal CO₂ removal devices landscape present market opportunities by increasing the effectiveness, safety, and overall use of these life-saving devices. Advances in miniaturization and biocompatibility have made portable, user-friendly options available (such as hip-mounted devices) and viable for a range of clinical settings, including ICU and outpatient of smart sensors with AI-enabled monitoring improves real-time data analytics, which may allow clinicians to monitor and respond to patient needs more effectively. Enhancement of membrane technology and blood flow characteristics have reduced the adverse effects and increased the potential for CO₂ removal. As these technological improvements expand the clinical context for utilization in this evolving device type (e.g., ARDS), they help to attract funding as well as increased interest from healthcare providers. Technology-induced market growth in the area of extracorporeal CO₂ removal devices will not only facilitate improved patient outcomes but also present additional market segments for manufacturers and healthcare organizations to leverage. Geographical Insights: In 2024, North America led the extracorporeal CO2 removal devices market with a substantial revenue share, followed by Europe and Asia Pacific. Further, Asia Pacific is expected to register the highest CAGR during the forecast period. Stay Updated on Extracorporeal CO2 Removal Devices Market Trends: Market Segmentation Based on product, the market is segmented into extracorporeal CO2 devices and consumables. The extracorporeal CO2 devices segment held a larger share of the market in 2024. By application, the market is categorized into acute respiratory distress syndrome, chronic obstructive pulmonary disease, and others. The chronic obstructive pulmonary disease segment accounted for the largest share of the market in 2024. In terms of end user, the market is segmented into hospitals and clinics, ambulatory surgical centers, and others. The hospitals and clinics segment held the largest share of the market in 2024. The extracorporeal CO2 removal devices market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Competitive Strategy and Development Key Players: Getinge; ALung Technologies, Inc.; Estor; NovaLung GmbH; Hemodec; Baxter Healthcare; Eurosets; LivaNova; Medtronic; and Xenios AG are among the major companies operating in the market. Trending Topics: Integration of artificial intelligence and telemedicine, adoption of value-based care models, advancements in portable and home-based extracorporeal CO2 removal systems. Global Headlines on Extracorporeal CO2 Removal Devices Praxis secures FDA clearance for EndoCore EBUS-TBNA biopsy device. Inogen completes acquisition of Physio-Assist. GSK completes acquisition of Aiolos Bio. Get Premium Copy of Extracorporeal CO2 Removal Devices Market Size and Growth Report by 2031 at: Conclusion The growth of the global extracorporeal CO₂ removal devices market is driven mostly by the growing prevalence of chronic respiratory conditions such as COPD and ARDS requiring advanced respiratory support technology. Extracorporeal CO2 removal devices are a desirable and beneficial technology that can remove carbon dioxide, which allows for lung-protective ventilation and prevents ventilator-induced lung injury. As technology evolves, devices are becoming more user-friendly and increasingly efficient as users become more skilled at operations. The Asia Pacific market is expected to grow rapidly, driven by improved healthcare infrastructure and increasing healthcare expenditures. The overall extracorporeal CO2 removal devices market is anticipated to witness growth, further reflecting a commitment to improved patient care in respiratory failure management. The report from The Insight Partners lists several stakeholders—including medical device manufacturers, healthcare providers, and research and academic institutions—along with valuable insights to navigate this evolving market landscape and unlock new opportunities successfully. Trending Related Reports: Extracorporeal Membrane Oxygenation Market Trends by 2031 Extracorporeal Shock Wave Lithotripsy Market Strategies, Top Players, Growth Opportunities, Analysis and Forecast by 2031 Extracorporeal Circulation Systems Market Overview, Growth, Trends, Analysis, Research Report (2025-2031) Extracorporeal Membrane Oxygenation (ECMO) Systems Market Size, Trends, Shares, and Forecast – 2031 Extracorporeal Lithotripsy Market Report 2031 by Segments, Geography, Dynamics, Recent Developments, and Strategic Insights Pediatric Extracorporeal Blood Pumps Market Overview, Growth, Trends, Analysis, Research Report (2025-2031) Extracorporeal Shock Wave Therapy Device Market Overview, Growth, Trends, Analysis, Research Report (2025-2031) Extracorporeal Membrane Oxygenation Machine Market Overview, Growth, Trends, Analysis, Research Report (2025-2031) About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact Us:If you have any queries about this report or if you would like further information, please get in touch with us:Contact Person: Ankit MathurE-mail: +1-646-491-9876 Logo: View original content: SOURCE The Insight Partners Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Daily Mail
01-08-2025
- Health
- Daily Mail
Parents' instincts must be taken into account by doctors, report says after boy, five, was sent home from hospital and died
Doctors have been ordered to take parents' instincts into account after a five-year-old-boy died when he was sent home from A&E due to bed shortages. Yusuf Mahmud Nazir passed away from respiratory failure, pneumonia and tonsillitis in November 2022 - just eight days after he was seen at Rotherham Hospital and sent home with antibiotics. After a previous report branding the child's care 'appropriate' was rejected by Yusuf's family, a new publication by NHS England finally confirmed he was failed by the health service. The document stated: 'Our primary finding is that the parental concerns, particularly the mother's instinct that her child was unwell, were repeatedly not addressed across services. 'A reliance on clinical metrics over caregiver insight caused distress for the family. 'This led to a lack of shared decision-making and there was limited evidence of collaborative discussions with Yusuf's family around clinical decisions, leading to a sense of exclusion and reduced trust in care plans.' Zaheer Ahmed, Yusuf's uncle, broke down in tears today as he said his nephew was failed by medical staff before developing multi-organ failure and suffering several cardiac arrests. 'Despite all these failings, despite all these issues that we've had, we still do not know how Yusuf has died. We want answers. We want an inquest. An inquest will tell us how Yusuf has died. And this is what the family are demanding,' he said. Today's report concludes that the 'instincts' of Yusuf's mother should not have been overlooked. Speaking at a news conference after the report was published, Soniya Nazir said her concerns 'were ignored each and every time', adding 'my son was left to die right beside me'. 'I carried Yusuf to the nurse, floppy with his eyes rolled back, struggling to breathe, myself to the nurse,' the mother told Sky News. 'She said: 'We're too busy, we can't get a doctor, you'll have to wait.' Yusuf's uncle Mr Ahmed has consistently claimed the family were told 'there are no beds and not enough doctors' in the emergency department. He insists Yusuf should have been admitted and given intravenous antibiotics in Rotherham. Today's report stated in its conclusions: 'Our primary finding is that the parental concerns, particularly the mother's instinct that her child was unwell, were repeatedly not addressed across services. 'A reliance on clinical metrics over caregiver insight caused distress for the family. 'This led to a lack of shared decision-making and there was limited evidence of collaborative discussions with Yusuf's family around clinical decisions, leading to a sense of exclusion and reduced trust in care plans.' A previous report into Yusuf's case in October 2023, by independent consultants and published by NHS South Yorkshire, found his care was appropriate and 'an admission was not clinically required' - but this was rejected by his family. Yusuf, who had asthma, was taken to the GP with a sore throat after feeling unwell on November 15. He was prescribed antibiotics by an advanced nurse practitioner. Later that evening, his parents took him to Rotherham Hospital urgent & emergency care centre (UECC), where he was seen in the early hours of the morning after a six-hour wait. Yusuf was discharged with a diagnosis of severe tonsillitis and an extended prescription of antibiotics. Two days later Yusuf was given further antibiotics by his GP for a possible chest infection, but his family became so concerned they called an ambulance and insisted the paramedics take him to Sheffield Children's Hospital rather than Rotherham. Yusuf was admitted to the intensive care unit on November 21 but developed multi-organ failure and suffered several cardiac arrests which he did not survive. The 2023 report said there was only one doctor in the paediatric UECC on November 15 and, after midnight, that medic was responsible for covering adults and children. It added that the doctor who saw Yusuf is an experienced UECC doctor who would not have needed to refer to a paediatrician to admit him.
Daily Mail
31-07-2025
- Health
- Daily Mail
Revealed: The top baby names in England and Wales with a 23% rise in Muhammad as it takes number one spot for second year in a row
Yusuf Mahmud Nazir died from respiratory failure, pneumonia and tonsillitis in November 2022 - just eight days after he was seen at Rotherham Hospital and sent home with antibiotics. After his family rejected a previous report branding the child's care 'appropriate', a new publication by NHS England has finally confirmed little Yusuf was failed by the health service. His uncle Zaheer Ahmed broke down in tears today as he said his nephew was failed before developing multi-organ failure and suffering several cardiac arrests. 'Despite all these failings, despite all these issues that we've had, we still do not know how Yusuf has died. We want answers. We want an inquest. An inquest will tell us how Yusuf has died. And this is what the family are demanding,' he said.
Medscape
18-06-2025
- Health
- Medscape
Metabolic Dysbiosis Score Predicts Mortality Risk in ICU
A fecal metabolic dysbiosis score (MDS) predicted 30-day mortality in critically ill patients and may help identify fecal metabolites as a potential treatable trait to improve survival in these patients. METHODOLOGY: Researchers prospectively collected fecal specimens from 196 critically ill patients (median age, 64 years; about half men) admitted to the medical intensive care unit (MICU) for non-COVID-19 respiratory failure or shock. They analyzed the specimens, defined microbiome compositions by shotgun metagenomic sequencing, and quantified microbiota-derived fecal metabolites by mass spectrometry. They then correlated microbiota features and metabolites with 30-day mortality. TAKEAWAY: Overall, 30-day mortality was 30.6%. There was no significant difference between survivors and nonsurvivors regarding age, sex, race, and comorbidity burden. Microbiota compositions of the first fecal sample after MICU admission did not independently associate with 30-day mortality, nor were there associations between single metabolites and 30-day mortality. However, by integrating the fecal metabolite concentrations of 13 microbiota-derived metabolites, the team developed an MDS that predicted 30-day mortality independent of known confounders. The MDS may complement existing tools to identify patients at high risk for mortality by incorporating potentially modifiable, microbiome-related, independent contributors to host resilience. IN PRACTICE: 'Fecal metabolic dysbiosis, determined by quantitation of 13 fecal metabolites, is independently associated with 30-day mortality after MICU admission in our cohort,' the study authors wrote. 'Therefore, fecal metabolic dysbiosis represents a potentially treatable trait to improve survival in heterogeneous critically ill patients,' and the MDS may serve as a biomarker to identify patients who might benefit from such treatment. SOURCE: The study was led by Alexander P. de Porto, PhD, University of Chicago, Chicago, and was published online in Science Advances . LIMITATIONS: The study had limitations. Patients were recruited at a single tertiary academic center and needed respiratory support or a vasopressor, and thus, the results might not be representative of the entire medical ICU population. Also, patients who did not produce a fecal sample or gave a sample that was not analyzable for metagenomics and metabolomics were excluded. DISCLOSURES: The study was funded by the Duchossois Family Institute. de Porto was funded by the Niels Stensen Fellowship. The Center for Research Informatics is funded by the Biological Sciences Division at the University of Chicago, with additional funding provided by the Institute for Translational Medicine and the National Institutes of Health (NIH). One co-author was funded by the NIH/National Heart, Lung, and Blood Institute. The authors declared having no competing interests.
Irish Times
14-05-2025
- Health
- Irish Times
The kindness of medical staff
Sir, – My 98-year-old mother was recently treated for respiratory failure in Our Lady of Lourdes Hospital in Drogheda. Over the space of five weeks, she received outstanding treatment and care from each member of staff in the Newgrange ward. From the consultants to the catering staff, she was treated with kindness and compassion, while our family was kept fully informed of each step of her treatment. When the time came for the palliative care team to be involved, they gently guided us through the process of her impending death, allowing her to do so with grace and dignity. With the HSE constantly in the spotlight for failures in the system, I wanted to highlight that there are still so many things that work well when they have the necessary resources. – Yours, etc, READ MORE MARY HAND, Castleknock, Dublin 15.
